what is the rationale for using bet inhibitors to treat myelofibrosis?
Published 1 year ago • 170 plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
4:04
simplify-1 2 trial: what is the long-term benefit of momelotinib treatment in r/r mf?
-
3:48
what is the use for monoclonal antibodies in mpn?
-
1:52
phase i dose-escalation study of the bet inhibitor incb057643 in r/r myelofibrosis
-
5:34
treating with a jak inhibitor for myelofibrosis
-
14:41
luspatercept compared with other available therapies for mf
-
0:53
investigating the place of jak inhibitors in the treatment of myelofibrosis
-
3:56
which patients with mf could benefit the most from telomerase inhibitors?
-
3:23
myelofibrosis: updates on jak inhibitors
-
3:35
new phase iii trial of imetelstat versus bat in jak inhibitor-refractory myelofibrosis
-
19:04
my view on current and future use of jak inhibitors for et, pv, and mf
-
3:38
manifest study: does the bet inhibitor cpi-0610 show synergy with ruxolitinib in mf?
-
24:12
debate: survival benefit of jak2 inhibitors in myelofibrosis
-
3:19
when would you switch a patient with myelofibrosis from ruxolitinib?
-
4:16
jak inhibitor selection & sequencing in myelofibrosis
-
2:04
novel therapies for myelofibrosis patients who have failed jak inhibitors
-
1:54
dr. mesa discusses jak inhibitors for myelofibrosis
-
2:42
the comfort-i and comfort-ii trials in myelofibrosis
-
2:29
krt-232: a novel mdm2 inhibitor approach in myelofibrosis
-
1:12
evidence supports rechallenging of jak inhibitors in myelofibrosis